Rydoo, the Game-Changing Business Travel and Expense Mobile App That Eliminates Complicated Admin
World leader in Quality of Life services, Sodexo, together with Xpenditure and iAlbatros unveils Rydoo, the new platform that eliminates daily administrative tasks starting with business travel and expense management. Launched in France and worldwide today, Rydoo aims to unlock the full potential of a dynamic yet old-fashioned market, while supporting the digitization of workplaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180605006168/en/
A business traveler using Rydoo Travel (Photo: Rydoo)
At work, administrative tasks with no added value are frustrating. We have all spent hours searching for the right flight, queuing at hotel lobbies to check-out and then finally have confusing expense reports to fill in. No salesperson was ever hired to become an expert in travel arrangement or collecting paper receipts. Employees and companies deserve to focus on what matters and what offers value. Rydoo brings this technology to drive efficiency and enable better ways to work.
Now Rydoo reinvents and simplifies travel and expense management to just a few clicks and photos, whilst saving time and optimizing costs.
Game-Changing in Business Travel and Expense Management
Rydoo is the first platform to cover the full scope of any trip or any expense to contribute to a more fulfilling work environment. With an average adoption rate of 93% within the first month, Rydoo proves just how user-friendly it is for employees and efficient it is for companies.
As a result, finance teams in organizations benefit from:
- a 87% reduction in processing cost,
- sources of optimisation thanks to compliance with company policies
- time saving with expense processing time divided by 4
Rydoo is also a SaaS solution that takes just a few days to implement, releasing new features on a weekly basis. Rydoo has a competitive business model, starting at €6 per month/active user.
Rydoo combines a stellar user experience with corporate expectations
Rydoo’s end-to-end platform combines both worlds through two modules to streamline the entire business travel and expense process:
- Rydoo travel helps employees find the right flight, rail ticket or car rental, and book the hotel that suits their needs from among 800 000 accommodation choices, and offers a dashing user experience in less time. Rydoo travel skips the payment phase for employees (no more queuing at the lobby) thanks to central billing - finance teams receive a single invoice gathering all business travel-related information, at the end of the month.
- Rydoo expense allows employees to enjoy the snap-and-process feature that offers automated, paperless expense management while complying with company’s policy. Finance teams easily manage employees’ reimbursements in real-time and control the company’s expense budget.
- Using both modules guarantee full value from this new way of working, but companies can also start with one module, depending on their needs.
Rydoo, CEO, Sébastien Marchon, says : “Rydoo fights with daily life pain points at work by offering an end-user oriented app. Rydoo removes complexity for employees while offering 87% over time productivity for finance teams. By making Rydoo one of the leading players in the travel and expense market, Sodexo aims to improve the quality of life and performance of the organizations it serves.”
Sodexo Mobility & Expense, President, Didier Dumont, adds: “Keeping people efficiently on the move is essential for business success. Rydoo brings the Travel and Expense ecosystem together to gain time and real-time visibility for hassle-free performance. To deliver this to the market in an agile way, we define ourselves as a corp-up that combines the strength of a corporate company and the agility and innovative mindset of a start-up”.
Rydoo reinvents and simplifies business travel and expense management thanks of the expertise its two founding startups it is originated: Xpenditure and iAlbatros. With its 300 enthusiastic employees, Rydoo operates in more than 60 countries; its 6,000 customers (public and private organizations) benefit from the usability and efficiency of its consumer-oriented app. Rydoo is a Sodexo corp-up, the alliance of two startups and a large corporation.
Founded in 1966 by Pierre Bellon in Marseilles, France, Sodexo is the worldwide leader in Quality of Life services, an essential factor in the performance of individuals and organizations. Present in 80 countries, Sodexo delivers to 100 million customers a day a unique array of On-Site Services, Benefits and Rewards Services, and Personal and Home Services. With 50 years' experience covering more than 100 professions, Sodexo offers its clients a comprehensive range of services including hospitality, reception, cleaning, maintenance, technical equipment and facilities maintenance, staff motivation and incentivization, solutions to streamline and optimize personnel relocation and business expenses, as well as home help, daycare, and concierge services. Sodexo's success and performance relies on its independence, its sustainable economic model, and its ability to ensure the development and commitment of its 450,000 employees around the world. Sodexo is represented on the CAC 40 and DJSI indices.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu